Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
Rupert Bartsch(Universitätszahnklinik Wien), Guenther G. Steger(Mount Vernon Hospital), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Simon Peter Gampenrieder(University of Salzburg), Margaretha Rudas(Comprehensive Cancer Center Vienna), Peter Dubsky(Hirslanden Klinik St. Anna), Christoph Zielinski(Vienna General Hospital), Ursula Pluschnig(Medical University of Vienna), Robert M. Mader(Centre de Recherche en Économie et Management), Christoph Wiltschke(University of Vienna), Andrea Rottenfusser(Comprehensive Cancer Center Vienna), Catharina De Vries(Medical University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 22
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k